EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
February 06, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
neurometrix_rgb.jpg
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
December 12, 2023 09:00 ET | NeuroMetrix, Inc.
NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
AIMLogo.jpg
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 21:00 ET | AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
AIMLogo.jpg
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 09:05 ET | AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
AIMLogo.jpg
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
November 21, 2023 12:00 ET | AIM ImmunoTech Inc.
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”)...
AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023 07:30 ET | AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIMLogo.jpg
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
November 09, 2023 08:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
AIMLogo.jpg
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 09:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
Potential COVID Spike Protein Detoxification Regime Discussed in Journal of American Physicians and Surgeons (AAPS)
August 31, 2023 14:29 ET | Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Disabling post-COVID symptoms (“long COVID”) and vaccine injury syndromes are increasingly prevalent, and there is no currently accepted treatment...
Ways to Counteract COVID Spike Protein Discussed in Journal of American Physicians and Surgeons (AAPS)
August 30, 2023 11:28 ET | Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The SARS-CoV-2 spike protein found in cells and tissues after COVID-19 respiratory illness and COVID-19 vaccination, which is thought to account for...